Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients

Stefano Nicolè, Massimiliano Lanzafame, Emanuela Lattuada, Dora Luise, Marta Vecchi, Evelina Tacconelli, Sandro Vento

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)615-617
Number of pages3
JournalInfectious Diseases
Volume51
Issue number8
DOIs
Publication statusPublished - Aug 3 2019

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Nicolè, S., Lanzafame, M., Lattuada, E., Luise, D., Vecchi, M., Tacconelli, E., & Vento, S. (2019). Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients. Infectious Diseases, 51(8), 615-617. https://doi.org/10.1080/23744235.2019.1609078